Unicycive Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	8.55	6.57	2.9	1.01	1.17
Research & Development	12.9	12.44	6.08	1.02	0.8
Operating Expenses	21.45	19	8.98	2.02	1.96
Operating Income	-21.45	-19	-8.98	-2.02	-1.96
Interest Expense / Income	0.08	0.01	0.63	0.24	0.14
Other Expense / Income	9.01	-0.95	0.41	-	0.06
Pretax Income	-30.54	-18.06	-10.02	-2.26	-2.17
Net Income	-30.54	-18.06	-10.02	-2.26	-2.17
Preferred Dividends	0.87	0	0	0	0
Net Income Common	-31.41	-18.06	-10.02	-2.26	-2.17
Shares Outstanding (Basic)	25	15	12	8	8
Shares Outstanding (Diluted)	25	15	12	8	8
Shares Change	62.98%	28.96%	37.37%	4.68%	-
EPS (Basic)	-1.28	-1.20	-0.86	-0.27	-0.27
EPS (Diluted)	-1.28	-1.20	-0.86	-0.27	-0.27
Free Cash Flow	-18.3	-15.65	-5.8	-1.46	-1.18
Free Cash Flow Per Share	-0.75	-1.04	-0.50	-0.17	-0.14
EBITDA	-30.18	-17.89	-9.38	-2.02	-2.03
Depreciation & Amortization	0.28	0.16	0.01	0	0
EBIT	-30.46	-18.05	-9.39	-2.02	-2.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).